Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Whitepaper
KRAS biomarker becomes a target of choice in certain cancer therapies
Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target.
In this white paper, find out more about:
- The structure and function of the RAS protein superfamily
- The role and consequences of KRAS gene activation
- How renowned companies are targeting KRAS in cancer therapies and what the current challenges in developing KRAS-targeted therapeutics are
- How to identify novel KRAS inhibitors and how to characterize downstream KRAS signaling with Alpha Surefire® Ultra™ and HTRF™ technologies
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
KRAS biomarker becomes a target of choice in certain cancer therapies